Information shocks and pharmaceutical firms’ marketing efforts: Evidence from the Chantix black box warning removal
We study how pharmaceutical firm marketing responds to a regulatory decision that represents a positive information shock about drug safety. In the context of the smoking cessation drug Chantix, we estimate the effects of a Food and Drug Administration (FDA) decision to remove the drug's black...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Lawler, Emily C. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2022transfer abstract |
|---|
| Übergeordnetes Werk: |
Enthalten in: Prediction of gas concentration evolution with evolutionary attention-based temporal graph convolutional network - Cheng, Lei ELSEVIER, 2022, Amsterdam |
|---|---|
| Übergeordnetes Werk: |
volume:81 ; year:2022 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jhealeco.2021.102557 |
|---|
| Katalog-ID: |
ELV056655320 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV056655320 | ||
| 003 | DE-627 | ||
| 005 | 20230626043729.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220205s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jhealeco.2021.102557 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001678.pica |
| 035 | |a (DE-627)ELV056655320 | ||
| 035 | |a (ELSEVIER)S0167-6296(21)00142-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 004 |q VZ |
| 084 | |a 54.72 |2 bkl | ||
| 100 | 1 | |a Lawler, Emily C. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Information shocks and pharmaceutical firms’ marketing efforts: Evidence from the Chantix black box warning removal |
| 264 | 1 | |c 2022transfer abstract | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a We study how pharmaceutical firm marketing responds to a regulatory decision that represents a positive information shock about drug safety. In the context of the smoking cessation drug Chantix, we estimate the effects of a Food and Drug Administration (FDA) decision to remove the drug's black box warning on two forms of marketing: monetary and in-kind payments to physicians (detailing) and direct-to-consumer advertising. Using identification strategies that leverage geographic variation in latent demand for smoking cessation therapy and the targeted nature of the information shock, we find that the removal of the warning significantly increased Chantix-related detailing payments and increased expenditures on national television advertising of Chantix. Understanding these firm-level strategic promotion responses is important, as they have implications for the dissemination of new drug information and the behaviors of physicians and consumers. | ||
| 520 | |a We study how pharmaceutical firm marketing responds to a regulatory decision that represents a positive information shock about drug safety. In the context of the smoking cessation drug Chantix, we estimate the effects of a Food and Drug Administration (FDA) decision to remove the drug's black box warning on two forms of marketing: monetary and in-kind payments to physicians (detailing) and direct-to-consumer advertising. Using identification strategies that leverage geographic variation in latent demand for smoking cessation therapy and the targeted nature of the information shock, we find that the removal of the warning significantly increased Chantix-related detailing payments and increased expenditures on national television advertising of Chantix. Understanding these firm-level strategic promotion responses is important, as they have implications for the dissemination of new drug information and the behaviors of physicians and consumers. | ||
| 700 | 1 | |a Skira, Meghan M. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n North-Holland Publ. Co |a Cheng, Lei ELSEVIER |t Prediction of gas concentration evolution with evolutionary attention-based temporal graph convolutional network |d 2022 |g Amsterdam |w (DE-627)ELV007813643 |
| 773 | 1 | 8 | |g volume:81 |g year:2022 |g pages:0 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jhealeco.2021.102557 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 54.72 |j Künstliche Intelligenz |q VZ |
| 951 | |a AR | ||
| 952 | |d 81 |j 2022 |h 0 | ||
| author_variant |
e c l ec ecl |
|---|---|
| matchkey_str |
lawleremilycskirameghanm:2022----:nomtosokadhraetclimmreigfoteiecfoteh |
| hierarchy_sort_str |
2022transfer abstract |
| bklnumber |
54.72 |
| publishDate |
2022 |
| allfields |
10.1016/j.jhealeco.2021.102557 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001678.pica (DE-627)ELV056655320 (ELSEVIER)S0167-6296(21)00142-9 DE-627 ger DE-627 rakwb eng 004 VZ 54.72 bkl Lawler, Emily C. verfasserin aut Information shocks and pharmaceutical firms’ marketing efforts: Evidence from the Chantix black box warning removal 2022transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier We study how pharmaceutical firm marketing responds to a regulatory decision that represents a positive information shock about drug safety. In the context of the smoking cessation drug Chantix, we estimate the effects of a Food and Drug Administration (FDA) decision to remove the drug's black box warning on two forms of marketing: monetary and in-kind payments to physicians (detailing) and direct-to-consumer advertising. Using identification strategies that leverage geographic variation in latent demand for smoking cessation therapy and the targeted nature of the information shock, we find that the removal of the warning significantly increased Chantix-related detailing payments and increased expenditures on national television advertising of Chantix. Understanding these firm-level strategic promotion responses is important, as they have implications for the dissemination of new drug information and the behaviors of physicians and consumers. We study how pharmaceutical firm marketing responds to a regulatory decision that represents a positive information shock about drug safety. In the context of the smoking cessation drug Chantix, we estimate the effects of a Food and Drug Administration (FDA) decision to remove the drug's black box warning on two forms of marketing: monetary and in-kind payments to physicians (detailing) and direct-to-consumer advertising. Using identification strategies that leverage geographic variation in latent demand for smoking cessation therapy and the targeted nature of the information shock, we find that the removal of the warning significantly increased Chantix-related detailing payments and increased expenditures on national television advertising of Chantix. Understanding these firm-level strategic promotion responses is important, as they have implications for the dissemination of new drug information and the behaviors of physicians and consumers. Skira, Meghan M. oth Enthalten in North-Holland Publ. Co Cheng, Lei ELSEVIER Prediction of gas concentration evolution with evolutionary attention-based temporal graph convolutional network 2022 Amsterdam (DE-627)ELV007813643 volume:81 year:2022 pages:0 https://doi.org/10.1016/j.jhealeco.2021.102557 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 54.72 Künstliche Intelligenz VZ AR 81 2022 0 |
| spelling |
10.1016/j.jhealeco.2021.102557 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001678.pica (DE-627)ELV056655320 (ELSEVIER)S0167-6296(21)00142-9 DE-627 ger DE-627 rakwb eng 004 VZ 54.72 bkl Lawler, Emily C. verfasserin aut Information shocks and pharmaceutical firms’ marketing efforts: Evidence from the Chantix black box warning removal 2022transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier We study how pharmaceutical firm marketing responds to a regulatory decision that represents a positive information shock about drug safety. In the context of the smoking cessation drug Chantix, we estimate the effects of a Food and Drug Administration (FDA) decision to remove the drug's black box warning on two forms of marketing: monetary and in-kind payments to physicians (detailing) and direct-to-consumer advertising. Using identification strategies that leverage geographic variation in latent demand for smoking cessation therapy and the targeted nature of the information shock, we find that the removal of the warning significantly increased Chantix-related detailing payments and increased expenditures on national television advertising of Chantix. Understanding these firm-level strategic promotion responses is important, as they have implications for the dissemination of new drug information and the behaviors of physicians and consumers. We study how pharmaceutical firm marketing responds to a regulatory decision that represents a positive information shock about drug safety. In the context of the smoking cessation drug Chantix, we estimate the effects of a Food and Drug Administration (FDA) decision to remove the drug's black box warning on two forms of marketing: monetary and in-kind payments to physicians (detailing) and direct-to-consumer advertising. Using identification strategies that leverage geographic variation in latent demand for smoking cessation therapy and the targeted nature of the information shock, we find that the removal of the warning significantly increased Chantix-related detailing payments and increased expenditures on national television advertising of Chantix. Understanding these firm-level strategic promotion responses is important, as they have implications for the dissemination of new drug information and the behaviors of physicians and consumers. Skira, Meghan M. oth Enthalten in North-Holland Publ. Co Cheng, Lei ELSEVIER Prediction of gas concentration evolution with evolutionary attention-based temporal graph convolutional network 2022 Amsterdam (DE-627)ELV007813643 volume:81 year:2022 pages:0 https://doi.org/10.1016/j.jhealeco.2021.102557 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 54.72 Künstliche Intelligenz VZ AR 81 2022 0 |
| allfields_unstemmed |
10.1016/j.jhealeco.2021.102557 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001678.pica (DE-627)ELV056655320 (ELSEVIER)S0167-6296(21)00142-9 DE-627 ger DE-627 rakwb eng 004 VZ 54.72 bkl Lawler, Emily C. verfasserin aut Information shocks and pharmaceutical firms’ marketing efforts: Evidence from the Chantix black box warning removal 2022transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier We study how pharmaceutical firm marketing responds to a regulatory decision that represents a positive information shock about drug safety. In the context of the smoking cessation drug Chantix, we estimate the effects of a Food and Drug Administration (FDA) decision to remove the drug's black box warning on two forms of marketing: monetary and in-kind payments to physicians (detailing) and direct-to-consumer advertising. Using identification strategies that leverage geographic variation in latent demand for smoking cessation therapy and the targeted nature of the information shock, we find that the removal of the warning significantly increased Chantix-related detailing payments and increased expenditures on national television advertising of Chantix. Understanding these firm-level strategic promotion responses is important, as they have implications for the dissemination of new drug information and the behaviors of physicians and consumers. We study how pharmaceutical firm marketing responds to a regulatory decision that represents a positive information shock about drug safety. In the context of the smoking cessation drug Chantix, we estimate the effects of a Food and Drug Administration (FDA) decision to remove the drug's black box warning on two forms of marketing: monetary and in-kind payments to physicians (detailing) and direct-to-consumer advertising. Using identification strategies that leverage geographic variation in latent demand for smoking cessation therapy and the targeted nature of the information shock, we find that the removal of the warning significantly increased Chantix-related detailing payments and increased expenditures on national television advertising of Chantix. Understanding these firm-level strategic promotion responses is important, as they have implications for the dissemination of new drug information and the behaviors of physicians and consumers. Skira, Meghan M. oth Enthalten in North-Holland Publ. Co Cheng, Lei ELSEVIER Prediction of gas concentration evolution with evolutionary attention-based temporal graph convolutional network 2022 Amsterdam (DE-627)ELV007813643 volume:81 year:2022 pages:0 https://doi.org/10.1016/j.jhealeco.2021.102557 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 54.72 Künstliche Intelligenz VZ AR 81 2022 0 |
| allfieldsGer |
10.1016/j.jhealeco.2021.102557 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001678.pica (DE-627)ELV056655320 (ELSEVIER)S0167-6296(21)00142-9 DE-627 ger DE-627 rakwb eng 004 VZ 54.72 bkl Lawler, Emily C. verfasserin aut Information shocks and pharmaceutical firms’ marketing efforts: Evidence from the Chantix black box warning removal 2022transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier We study how pharmaceutical firm marketing responds to a regulatory decision that represents a positive information shock about drug safety. In the context of the smoking cessation drug Chantix, we estimate the effects of a Food and Drug Administration (FDA) decision to remove the drug's black box warning on two forms of marketing: monetary and in-kind payments to physicians (detailing) and direct-to-consumer advertising. Using identification strategies that leverage geographic variation in latent demand for smoking cessation therapy and the targeted nature of the information shock, we find that the removal of the warning significantly increased Chantix-related detailing payments and increased expenditures on national television advertising of Chantix. Understanding these firm-level strategic promotion responses is important, as they have implications for the dissemination of new drug information and the behaviors of physicians and consumers. We study how pharmaceutical firm marketing responds to a regulatory decision that represents a positive information shock about drug safety. In the context of the smoking cessation drug Chantix, we estimate the effects of a Food and Drug Administration (FDA) decision to remove the drug's black box warning on two forms of marketing: monetary and in-kind payments to physicians (detailing) and direct-to-consumer advertising. Using identification strategies that leverage geographic variation in latent demand for smoking cessation therapy and the targeted nature of the information shock, we find that the removal of the warning significantly increased Chantix-related detailing payments and increased expenditures on national television advertising of Chantix. Understanding these firm-level strategic promotion responses is important, as they have implications for the dissemination of new drug information and the behaviors of physicians and consumers. Skira, Meghan M. oth Enthalten in North-Holland Publ. Co Cheng, Lei ELSEVIER Prediction of gas concentration evolution with evolutionary attention-based temporal graph convolutional network 2022 Amsterdam (DE-627)ELV007813643 volume:81 year:2022 pages:0 https://doi.org/10.1016/j.jhealeco.2021.102557 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 54.72 Künstliche Intelligenz VZ AR 81 2022 0 |
| allfieldsSound |
10.1016/j.jhealeco.2021.102557 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001678.pica (DE-627)ELV056655320 (ELSEVIER)S0167-6296(21)00142-9 DE-627 ger DE-627 rakwb eng 004 VZ 54.72 bkl Lawler, Emily C. verfasserin aut Information shocks and pharmaceutical firms’ marketing efforts: Evidence from the Chantix black box warning removal 2022transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier We study how pharmaceutical firm marketing responds to a regulatory decision that represents a positive information shock about drug safety. In the context of the smoking cessation drug Chantix, we estimate the effects of a Food and Drug Administration (FDA) decision to remove the drug's black box warning on two forms of marketing: monetary and in-kind payments to physicians (detailing) and direct-to-consumer advertising. Using identification strategies that leverage geographic variation in latent demand for smoking cessation therapy and the targeted nature of the information shock, we find that the removal of the warning significantly increased Chantix-related detailing payments and increased expenditures on national television advertising of Chantix. Understanding these firm-level strategic promotion responses is important, as they have implications for the dissemination of new drug information and the behaviors of physicians and consumers. We study how pharmaceutical firm marketing responds to a regulatory decision that represents a positive information shock about drug safety. In the context of the smoking cessation drug Chantix, we estimate the effects of a Food and Drug Administration (FDA) decision to remove the drug's black box warning on two forms of marketing: monetary and in-kind payments to physicians (detailing) and direct-to-consumer advertising. Using identification strategies that leverage geographic variation in latent demand for smoking cessation therapy and the targeted nature of the information shock, we find that the removal of the warning significantly increased Chantix-related detailing payments and increased expenditures on national television advertising of Chantix. Understanding these firm-level strategic promotion responses is important, as they have implications for the dissemination of new drug information and the behaviors of physicians and consumers. Skira, Meghan M. oth Enthalten in North-Holland Publ. Co Cheng, Lei ELSEVIER Prediction of gas concentration evolution with evolutionary attention-based temporal graph convolutional network 2022 Amsterdam (DE-627)ELV007813643 volume:81 year:2022 pages:0 https://doi.org/10.1016/j.jhealeco.2021.102557 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 54.72 Künstliche Intelligenz VZ AR 81 2022 0 |
| language |
English |
| source |
Enthalten in Prediction of gas concentration evolution with evolutionary attention-based temporal graph convolutional network Amsterdam volume:81 year:2022 pages:0 |
| sourceStr |
Enthalten in Prediction of gas concentration evolution with evolutionary attention-based temporal graph convolutional network Amsterdam volume:81 year:2022 pages:0 |
| format_phy_str_mv |
Article |
| bklname |
Künstliche Intelligenz |
| institution |
findex.gbv.de |
| dewey-raw |
004 |
| isfreeaccess_bool |
false |
| container_title |
Prediction of gas concentration evolution with evolutionary attention-based temporal graph convolutional network |
| authorswithroles_txt_mv |
Lawler, Emily C. @@aut@@ Skira, Meghan M. @@oth@@ |
| publishDateDaySort_date |
2022-01-01T00:00:00Z |
| hierarchy_top_id |
ELV007813643 |
| dewey-sort |
14 |
| id |
ELV056655320 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV056655320</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626043729.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220205s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jhealeco.2021.102557</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001678.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV056655320</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0167-6296(21)00142-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">004</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">54.72</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Lawler, Emily C.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Information shocks and pharmaceutical firms’ marketing efforts: Evidence from the Chantix black box warning removal</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022transfer abstract</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">We study how pharmaceutical firm marketing responds to a regulatory decision that represents a positive information shock about drug safety. In the context of the smoking cessation drug Chantix, we estimate the effects of a Food and Drug Administration (FDA) decision to remove the drug's black box warning on two forms of marketing: monetary and in-kind payments to physicians (detailing) and direct-to-consumer advertising. Using identification strategies that leverage geographic variation in latent demand for smoking cessation therapy and the targeted nature of the information shock, we find that the removal of the warning significantly increased Chantix-related detailing payments and increased expenditures on national television advertising of Chantix. Understanding these firm-level strategic promotion responses is important, as they have implications for the dissemination of new drug information and the behaviors of physicians and consumers.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">We study how pharmaceutical firm marketing responds to a regulatory decision that represents a positive information shock about drug safety. In the context of the smoking cessation drug Chantix, we estimate the effects of a Food and Drug Administration (FDA) decision to remove the drug's black box warning on two forms of marketing: monetary and in-kind payments to physicians (detailing) and direct-to-consumer advertising. Using identification strategies that leverage geographic variation in latent demand for smoking cessation therapy and the targeted nature of the information shock, we find that the removal of the warning significantly increased Chantix-related detailing payments and increased expenditures on national television advertising of Chantix. Understanding these firm-level strategic promotion responses is important, as they have implications for the dissemination of new drug information and the behaviors of physicians and consumers.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Skira, Meghan M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">North-Holland Publ. Co</subfield><subfield code="a">Cheng, Lei ELSEVIER</subfield><subfield code="t">Prediction of gas concentration evolution with evolutionary attention-based temporal graph convolutional network</subfield><subfield code="d">2022</subfield><subfield code="g">Amsterdam</subfield><subfield code="w">(DE-627)ELV007813643</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:81</subfield><subfield code="g">year:2022</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jhealeco.2021.102557</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">54.72</subfield><subfield code="j">Künstliche Intelligenz</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">81</subfield><subfield code="j">2022</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| author |
Lawler, Emily C. |
| spellingShingle |
Lawler, Emily C. ddc 004 bkl 54.72 Information shocks and pharmaceutical firms’ marketing efforts: Evidence from the Chantix black box warning removal |
| authorStr |
Lawler, Emily C. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV007813643 |
| format |
electronic Article |
| dewey-ones |
004 - Data processing & computer science |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
004 VZ 54.72 bkl Information shocks and pharmaceutical firms’ marketing efforts: Evidence from the Chantix black box warning removal |
| topic |
ddc 004 bkl 54.72 |
| topic_unstemmed |
ddc 004 bkl 54.72 |
| topic_browse |
ddc 004 bkl 54.72 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
m m s mm mms |
| hierarchy_parent_title |
Prediction of gas concentration evolution with evolutionary attention-based temporal graph convolutional network |
| hierarchy_parent_id |
ELV007813643 |
| dewey-tens |
000 - Computer science, knowledge & systems |
| hierarchy_top_title |
Prediction of gas concentration evolution with evolutionary attention-based temporal graph convolutional network |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV007813643 |
| title |
Information shocks and pharmaceutical firms’ marketing efforts: Evidence from the Chantix black box warning removal |
| ctrlnum |
(DE-627)ELV056655320 (ELSEVIER)S0167-6296(21)00142-9 |
| title_full |
Information shocks and pharmaceutical firms’ marketing efforts: Evidence from the Chantix black box warning removal |
| author_sort |
Lawler, Emily C. |
| journal |
Prediction of gas concentration evolution with evolutionary attention-based temporal graph convolutional network |
| journalStr |
Prediction of gas concentration evolution with evolutionary attention-based temporal graph convolutional network |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
000 - Computer science, information & general works |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Lawler, Emily C. |
| container_volume |
81 |
| class |
004 VZ 54.72 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Lawler, Emily C. |
| doi_str_mv |
10.1016/j.jhealeco.2021.102557 |
| dewey-full |
004 |
| title_sort |
information shocks and pharmaceutical firms’ marketing efforts: evidence from the chantix black box warning removal |
| title_auth |
Information shocks and pharmaceutical firms’ marketing efforts: Evidence from the Chantix black box warning removal |
| abstract |
We study how pharmaceutical firm marketing responds to a regulatory decision that represents a positive information shock about drug safety. In the context of the smoking cessation drug Chantix, we estimate the effects of a Food and Drug Administration (FDA) decision to remove the drug's black box warning on two forms of marketing: monetary and in-kind payments to physicians (detailing) and direct-to-consumer advertising. Using identification strategies that leverage geographic variation in latent demand for smoking cessation therapy and the targeted nature of the information shock, we find that the removal of the warning significantly increased Chantix-related detailing payments and increased expenditures on national television advertising of Chantix. Understanding these firm-level strategic promotion responses is important, as they have implications for the dissemination of new drug information and the behaviors of physicians and consumers. |
| abstractGer |
We study how pharmaceutical firm marketing responds to a regulatory decision that represents a positive information shock about drug safety. In the context of the smoking cessation drug Chantix, we estimate the effects of a Food and Drug Administration (FDA) decision to remove the drug's black box warning on two forms of marketing: monetary and in-kind payments to physicians (detailing) and direct-to-consumer advertising. Using identification strategies that leverage geographic variation in latent demand for smoking cessation therapy and the targeted nature of the information shock, we find that the removal of the warning significantly increased Chantix-related detailing payments and increased expenditures on national television advertising of Chantix. Understanding these firm-level strategic promotion responses is important, as they have implications for the dissemination of new drug information and the behaviors of physicians and consumers. |
| abstract_unstemmed |
We study how pharmaceutical firm marketing responds to a regulatory decision that represents a positive information shock about drug safety. In the context of the smoking cessation drug Chantix, we estimate the effects of a Food and Drug Administration (FDA) decision to remove the drug's black box warning on two forms of marketing: monetary and in-kind payments to physicians (detailing) and direct-to-consumer advertising. Using identification strategies that leverage geographic variation in latent demand for smoking cessation therapy and the targeted nature of the information shock, we find that the removal of the warning significantly increased Chantix-related detailing payments and increased expenditures on national television advertising of Chantix. Understanding these firm-level strategic promotion responses is important, as they have implications for the dissemination of new drug information and the behaviors of physicians and consumers. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| title_short |
Information shocks and pharmaceutical firms’ marketing efforts: Evidence from the Chantix black box warning removal |
| url |
https://doi.org/10.1016/j.jhealeco.2021.102557 |
| remote_bool |
true |
| author2 |
Skira, Meghan M. |
| author2Str |
Skira, Meghan M. |
| ppnlink |
ELV007813643 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth |
| doi_str |
10.1016/j.jhealeco.2021.102557 |
| up_date |
2024-07-06T21:01:29.498Z |
| _version_ |
1803864967216103424 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV056655320</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626043729.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220205s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jhealeco.2021.102557</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001678.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV056655320</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0167-6296(21)00142-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">004</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">54.72</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Lawler, Emily C.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Information shocks and pharmaceutical firms’ marketing efforts: Evidence from the Chantix black box warning removal</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022transfer abstract</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">We study how pharmaceutical firm marketing responds to a regulatory decision that represents a positive information shock about drug safety. In the context of the smoking cessation drug Chantix, we estimate the effects of a Food and Drug Administration (FDA) decision to remove the drug's black box warning on two forms of marketing: monetary and in-kind payments to physicians (detailing) and direct-to-consumer advertising. Using identification strategies that leverage geographic variation in latent demand for smoking cessation therapy and the targeted nature of the information shock, we find that the removal of the warning significantly increased Chantix-related detailing payments and increased expenditures on national television advertising of Chantix. Understanding these firm-level strategic promotion responses is important, as they have implications for the dissemination of new drug information and the behaviors of physicians and consumers.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">We study how pharmaceutical firm marketing responds to a regulatory decision that represents a positive information shock about drug safety. In the context of the smoking cessation drug Chantix, we estimate the effects of a Food and Drug Administration (FDA) decision to remove the drug's black box warning on two forms of marketing: monetary and in-kind payments to physicians (detailing) and direct-to-consumer advertising. Using identification strategies that leverage geographic variation in latent demand for smoking cessation therapy and the targeted nature of the information shock, we find that the removal of the warning significantly increased Chantix-related detailing payments and increased expenditures on national television advertising of Chantix. Understanding these firm-level strategic promotion responses is important, as they have implications for the dissemination of new drug information and the behaviors of physicians and consumers.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Skira, Meghan M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">North-Holland Publ. Co</subfield><subfield code="a">Cheng, Lei ELSEVIER</subfield><subfield code="t">Prediction of gas concentration evolution with evolutionary attention-based temporal graph convolutional network</subfield><subfield code="d">2022</subfield><subfield code="g">Amsterdam</subfield><subfield code="w">(DE-627)ELV007813643</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:81</subfield><subfield code="g">year:2022</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jhealeco.2021.102557</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">54.72</subfield><subfield code="j">Künstliche Intelligenz</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">81</subfield><subfield code="j">2022</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.3997297 |